Debt-to-equity of Clearside Biomedical, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Clearside Biomedical, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2017 to 30 Sep 2025.
Clearside Biomedical, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -138%, a 41% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Clearside Biomedical, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	-138%	+98%	+41%	30 Sep 2025
Q2 2025	-153%	+128%	+45%	30 Jun 2025
Q1 2025	-173%	+193%	+53%	31 Mar 2025
Q4 2024	-204%	+387%	+66%	31 Dec 2024
Q3 2024	-236%	+3620%	+94%	30 Sep 2024
Q2 2024	-281%	-891%	-146%	30 Jun 2024
Q1 2024	-366%	-586%	-267%	31 Mar 2024
Q4 2023	-591%	-693%	-680%	31 Dec 2023
Q3 2023	-3856%	-3902%	-8528%	30 Sep 2023
Q2 2023	610%	+589%	+2730%	30 Jun 2023
Q1 2023	219%	+193%	+736%	31 Mar 2023
Q4 2022	102%	+64%	+172%	31 Dec 2022
Q3 2022	46%	-18%	-28%	30 Sep 2022
Q2 2022	22%	-53%	-71%	30 Jun 2022
Q1 2022	26%	-74%	-74%	31 Mar 2022
Q4 2021	37%	-92%	-71%	31 Dec 2021
Q3 2021	64%	-71%	-53%	30 Sep 2021
Q2 2021	75%	-72%	-49%	30 Jun 2021
Q1 2021	100%	-43%	-30%	31 Mar 2021
Q4 2020	130%	-11%	-7.7%	31 Dec 2020
Q3 2020	135%	+15%	+12%	30 Sep 2020
Q2 2020	147%	+60%	+69%	30 Jun 2020
Q1 2020	143%	+84%	+143%	31 Mar 2020
Q4 2019	141%	+102%	+261%	31 Dec 2019
Q3 2019	120%	+82%	+211%	30 Sep 2019
Q2 2019	87%	+51%	+139%	30 Jun 2019
Q1 2019	59%	+24%	+68%	31 Mar 2019
Q4 2018	39%	+2%	+6.1%	31 Dec 2018
Q3 2018	39%	+13%	+48%	30 Sep 2018
Q2 2018	36%	+14%	+66%	30 Jun 2018
Q1 2018	35%	+14%	+66%	31 Mar 2018
Q4 2017	37%			31 Dec 2017
Q3 2017	26%			30 Sep 2017
Q2 2017	22%			30 Jun 2017
Q1 2017	21%			31 Mar 2017

* An asterisk sign (*) next to the value indicates that the value is likely invalid.